Fifty-two outpatients with the main target symptom of anxiety with accompanying depression were randomly assigned to receive either doxepin or placebo in a double-blind study for four weeks. The doxepin group improved significantly on global ratings at one week and at four weeks. It was found that at one week patients were significantly improved on symptoms of anxiety, while at four weeks significant improvement occurred in depressive symptomatology.Abstract Teaser